ID   HCC3153
AC   CVCL_3377
SY   HCC 3153; HCC-3153; Hamon Cancer Center 3153
DR   CLO; CLO_0009910
DR   EFO; EFO_0001179
DR   ArrayExpress; E-TABM-157
DR   BioSample; SAMN03470870
DR   cancercelllines; CVCL_3377
DR   Cosmic; 1136375
DR   Cosmic; 1176634
DR   DepMap; ACH-002324
DR   GEO; GSM350507
DR   GEO; GSM1053691
DR   GEO; GSM1172966
DR   GEO; GSM1172874
DR   GEO; GSM3145709
DR   LINCS_HMS; 51094
DR   LINCS_LDP; LCL-2075
DR   PharmacoDB; HCC3153_498_2019
DR   Progenetix; CVCL_3377
DR   Wikidata; Q54881686
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=20679594;
RX   PubMed=21778573;
RX   PubMed=22032724;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25877200;
RX   PubMed=25960936;
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Doubling time: 72.26 hours (GrayJW panel).
CC   HLA typing: A*34:02,34:02; B*08:01,15:03; C*07:01,02:02; DQB1*06:04,06:04 (PubMed=25960936).
CC   Sequence variation: Gene fusion; HGNC; 290; GRK3 + HGNC; 29435; WWC1; Name(s)=WWC1-GRK3, WWC1-ADRBK2; Note=In frame (PubMed=22032724).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Thr276Alafs*14 (c.815_824dupAGCCATGTGG); ClinVar=VCV000055723; Zygosity=Unspecified (PubMed=22032724).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): PubMed=20679594; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 11
ST   D18S51: 17
ST   D19S433: 12,14.2
ST   D21S11: 28,32
ST   D2S1338: 20
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 19
ST   Penta D: 2.2,5
ST   Penta E: 7,13
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 13,16
DI   NCIt; C4017; Breast ductal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=22032724; DOI=10.1186/1755-8794-4-75;
RA   Ha K.C.H., Lalonde E., Li L.-L., Cavallone L., Natrajan R.,
RA   Lambros M.B., Mitsopoulos C., Hakas J., Kozarewa I., Fenwick K.,
RA   Lord C.J., Ashworth A., Vincent-Salomon A., Basik M., Reis-Filho J.S.,
RA   Majewski J., Foulkes W.D.;
RT   "Identification of gene fusion transcripts by transcriptome sequencing
RT   in BRCA1-mutated breast cancers and cell lines.";
RL   BMC Med. Genomics 4:75.1-75.13(2011).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//